| Antiviral | EC50 ratio | Phenotype | Strain | Source | Marker | Assay | Reference |
|---|---|---|---|---|---|---|---|
| Ganciclovir | 2.00 | Low level resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) | ||
| Cidofovir | 3.30 | Intermediate level resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) | ||
| Foscarnet | 3.00 | Intermediate level resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) |
| Mutant | Resistances |
|---|---|
| N408D |
Ganciclovir:
|
| N408D |
Cidofovir:
|
| N408D |
Foscarnet:
|
| N408K |
Ganciclovir:
|
| N408K |
Cidofovir:
|
| N408K |
Foscarnet:
|
| N408K |
Brincidofovir:
|
| N408S |
Ganciclovir:
|
| N408S |
Cidofovir:
|
| N408S |
Foscarnet:
|